I-Mab Announces Participation at Jefferies and Piper Conferences in November

November 06, 2023 01:00 PM GMT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 I-Mab Announces Participation at Jefferies and Piper Conferences in November
Image source: Kalkine Media

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq:IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

Jefferies London Healthcare Conference (In Person)

Presentation Time

Tuesday, November 14th at 10:30 a.m. GMT (5:30 a.m. EST)

Presenters

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO

Webcast link

https://wsw.com/webcast/jeff287/imab/1828028
The webcast will also be available under "Event Calendar" on I-Mab's IR website
at 
http://ir.i-mabbiopharma.com/

Meetings

One-on-one and small group meetings: Nov 14 – 16, 2023

Management
Participants

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Jefferies representative.

Piper Sandler 35th Annual Healthcare Conference (In Person)

Presentation Time

Thursday, November 30th at 8:30 a.m. EST

Presenters

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO

Meetings

One-on-one and small group meetings: Nov 28 – 30, 2023                                   

Management
Participants

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Piper Sandler representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedInX, formerly known as Twitter, and WeChat.

I-Mab Contacts

Investors

Media

Tyler Ehler

Gigi Feng

Senior Director, Investor Relations

Chief Communications Officer

[email protected]

[email protected]

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next